Studio costo-efficacia della vaccinazione influenzale per gli italiani di età compresa tra 50 e 64 anni

Translated title of the contribution: Cost-effectiveness study of influenza vaccination for people aged 50-64 years in Italy

Roberto Gasparini, C. Lucioni, F. Ansaldi, P. Durando, L. Sticchi, G. Icardi, D. Panatto, M. Martin, J. Chancellor, S. Aballéa

Research output: Contribution to journalArticle

Abstract

Background: In 1999, the American Academy of Family Physicians already included, among target groups for influenza vaccination, subjects aged 50-64 years, because of the increased prevalence of people with high-risk conditions in this age group. However, studies on the cost-effectiveness and cost-utility of influenza vaccination in this population are necessary in order to provide useful indications for Public Health decision makers. Methods: In this study, we built a probabilistic model to evaluate the cost-effectiveness of reimbursement only for adults aged 50-64 years with high-risk conditions, in comparison with reimbursement for all individuals in this age group, in Italy. Model inputs were obtained from the international and national literature, web-sites and the Italian network for influenza surveillance (CIRINET-INFLUNET). Results: The model revealed benefits from vaccination in the form of decreased rates of influenza cases, hospitalizations and deaths from influenza, more life expectancy and quality-adjusted life years (QALYs). In the case of reimbursement for all people aged 50-64 years, the incremental cost-effectiveness ratio (ICER) was € 15,652 per QALY for a third-party payer (TPP) and the vaccination program was cost-saving for the society. This immunization strategy should avoid 95,813 cases of influenza-like illnesses, 232 deaths, 3,235 hospitalizations and 111,981 workdays lost. Assuming a cost-effectiveness threshold ratio of € 50,000 per QALY gained, the probability of the new strategy being cost-effective was 89% for the TPP and 99% for society. Conclusions: Lowering the age threshold for routine influenza vaccination from 65 to 50 years is likely to be cost-effective and not too expensive for the National Health System.

Original languageItalian
Pages (from-to)91-101
Number of pages11
JournalPharmacoEconomics - Italian Research Articles
Volume9
Issue number2
Publication statusPublished - 2007

Fingerprint

Human Influenza
Italy
Cost-Benefit Analysis
Vaccination
Quality-Adjusted Life Years
Health Insurance Reimbursement
Costs and Cost Analysis
Hospitalization
Age Groups
Family Physicians
Statistical Models
Life Expectancy
Immunization
Public Health
Quality of Life
Health
Population

ASJC Scopus subject areas

  • Pharmacology
  • Health Policy

Cite this

Gasparini, R., Lucioni, C., Ansaldi, F., Durando, P., Sticchi, L., Icardi, G., ... Aballéa, S. (2007). Studio costo-efficacia della vaccinazione influenzale per gli italiani di età compresa tra 50 e 64 anni. PharmacoEconomics - Italian Research Articles, 9(2), 91-101.

Studio costo-efficacia della vaccinazione influenzale per gli italiani di età compresa tra 50 e 64 anni. / Gasparini, Roberto; Lucioni, C.; Ansaldi, F.; Durando, P.; Sticchi, L.; Icardi, G.; Panatto, D.; Martin, M.; Chancellor, J.; Aballéa, S.

In: PharmacoEconomics - Italian Research Articles, Vol. 9, No. 2, 2007, p. 91-101.

Research output: Contribution to journalArticle

Gasparini, R, Lucioni, C, Ansaldi, F, Durando, P, Sticchi, L, Icardi, G, Panatto, D, Martin, M, Chancellor, J & Aballéa, S 2007, 'Studio costo-efficacia della vaccinazione influenzale per gli italiani di età compresa tra 50 e 64 anni', PharmacoEconomics - Italian Research Articles, vol. 9, no. 2, pp. 91-101.
Gasparini, Roberto ; Lucioni, C. ; Ansaldi, F. ; Durando, P. ; Sticchi, L. ; Icardi, G. ; Panatto, D. ; Martin, M. ; Chancellor, J. ; Aballéa, S. / Studio costo-efficacia della vaccinazione influenzale per gli italiani di età compresa tra 50 e 64 anni. In: PharmacoEconomics - Italian Research Articles. 2007 ; Vol. 9, No. 2. pp. 91-101.
@article{832d2872041e4cdb9f7fdb2215e46f2b,
title = "Studio costo-efficacia della vaccinazione influenzale per gli italiani di et{\`a} compresa tra 50 e 64 anni",
abstract = "Background: In 1999, the American Academy of Family Physicians already included, among target groups for influenza vaccination, subjects aged 50-64 years, because of the increased prevalence of people with high-risk conditions in this age group. However, studies on the cost-effectiveness and cost-utility of influenza vaccination in this population are necessary in order to provide useful indications for Public Health decision makers. Methods: In this study, we built a probabilistic model to evaluate the cost-effectiveness of reimbursement only for adults aged 50-64 years with high-risk conditions, in comparison with reimbursement for all individuals in this age group, in Italy. Model inputs were obtained from the international and national literature, web-sites and the Italian network for influenza surveillance (CIRINET-INFLUNET). Results: The model revealed benefits from vaccination in the form of decreased rates of influenza cases, hospitalizations and deaths from influenza, more life expectancy and quality-adjusted life years (QALYs). In the case of reimbursement for all people aged 50-64 years, the incremental cost-effectiveness ratio (ICER) was € 15,652 per QALY for a third-party payer (TPP) and the vaccination program was cost-saving for the society. This immunization strategy should avoid 95,813 cases of influenza-like illnesses, 232 deaths, 3,235 hospitalizations and 111,981 workdays lost. Assuming a cost-effectiveness threshold ratio of € 50,000 per QALY gained, the probability of the new strategy being cost-effective was 89{\%} for the TPP and 99{\%} for society. Conclusions: Lowering the age threshold for routine influenza vaccination from 65 to 50 years is likely to be cost-effective and not too expensive for the National Health System.",
author = "Roberto Gasparini and C. Lucioni and F. Ansaldi and P. Durando and L. Sticchi and G. Icardi and D. Panatto and M. Martin and J. Chancellor and S. Aball{\'e}a",
year = "2007",
language = "Italian",
volume = "9",
pages = "91--101",
journal = "PharmacoEconomics - Italian Research Articles",
issn = "1590-9158",
publisher = "Adis International Ltd",
number = "2",

}

TY - JOUR

T1 - Studio costo-efficacia della vaccinazione influenzale per gli italiani di età compresa tra 50 e 64 anni

AU - Gasparini, Roberto

AU - Lucioni, C.

AU - Ansaldi, F.

AU - Durando, P.

AU - Sticchi, L.

AU - Icardi, G.

AU - Panatto, D.

AU - Martin, M.

AU - Chancellor, J.

AU - Aballéa, S.

PY - 2007

Y1 - 2007

N2 - Background: In 1999, the American Academy of Family Physicians already included, among target groups for influenza vaccination, subjects aged 50-64 years, because of the increased prevalence of people with high-risk conditions in this age group. However, studies on the cost-effectiveness and cost-utility of influenza vaccination in this population are necessary in order to provide useful indications for Public Health decision makers. Methods: In this study, we built a probabilistic model to evaluate the cost-effectiveness of reimbursement only for adults aged 50-64 years with high-risk conditions, in comparison with reimbursement for all individuals in this age group, in Italy. Model inputs were obtained from the international and national literature, web-sites and the Italian network for influenza surveillance (CIRINET-INFLUNET). Results: The model revealed benefits from vaccination in the form of decreased rates of influenza cases, hospitalizations and deaths from influenza, more life expectancy and quality-adjusted life years (QALYs). In the case of reimbursement for all people aged 50-64 years, the incremental cost-effectiveness ratio (ICER) was € 15,652 per QALY for a third-party payer (TPP) and the vaccination program was cost-saving for the society. This immunization strategy should avoid 95,813 cases of influenza-like illnesses, 232 deaths, 3,235 hospitalizations and 111,981 workdays lost. Assuming a cost-effectiveness threshold ratio of € 50,000 per QALY gained, the probability of the new strategy being cost-effective was 89% for the TPP and 99% for society. Conclusions: Lowering the age threshold for routine influenza vaccination from 65 to 50 years is likely to be cost-effective and not too expensive for the National Health System.

AB - Background: In 1999, the American Academy of Family Physicians already included, among target groups for influenza vaccination, subjects aged 50-64 years, because of the increased prevalence of people with high-risk conditions in this age group. However, studies on the cost-effectiveness and cost-utility of influenza vaccination in this population are necessary in order to provide useful indications for Public Health decision makers. Methods: In this study, we built a probabilistic model to evaluate the cost-effectiveness of reimbursement only for adults aged 50-64 years with high-risk conditions, in comparison with reimbursement for all individuals in this age group, in Italy. Model inputs were obtained from the international and national literature, web-sites and the Italian network for influenza surveillance (CIRINET-INFLUNET). Results: The model revealed benefits from vaccination in the form of decreased rates of influenza cases, hospitalizations and deaths from influenza, more life expectancy and quality-adjusted life years (QALYs). In the case of reimbursement for all people aged 50-64 years, the incremental cost-effectiveness ratio (ICER) was € 15,652 per QALY for a third-party payer (TPP) and the vaccination program was cost-saving for the society. This immunization strategy should avoid 95,813 cases of influenza-like illnesses, 232 deaths, 3,235 hospitalizations and 111,981 workdays lost. Assuming a cost-effectiveness threshold ratio of € 50,000 per QALY gained, the probability of the new strategy being cost-effective was 89% for the TPP and 99% for society. Conclusions: Lowering the age threshold for routine influenza vaccination from 65 to 50 years is likely to be cost-effective and not too expensive for the National Health System.

UR - http://www.scopus.com/inward/record.url?scp=34748866694&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34748866694&partnerID=8YFLogxK

M3 - Articolo

AN - SCOPUS:34748866694

VL - 9

SP - 91

EP - 101

JO - PharmacoEconomics - Italian Research Articles

JF - PharmacoEconomics - Italian Research Articles

SN - 1590-9158

IS - 2

ER -